Solian: Advanced Atypical Antipsychotic for Schizophrenia Management
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.78 | $83.42 (0%) | 🛒 Add to cart |
| 60 | $2.55 | $166.84 $153.08 (8%) | 🛒 Add to cart |
| 90 | $2.47 | $250.26 $222.74 (11%) | 🛒 Add to cart |
| 120 | $2.44 | $333.68 $293.26 (12%) | 🛒 Add to cart |
| 180 | $2.40 | $500.52 $431.72 (14%) | 🛒 Add to cart |
| 270 | $2.37
Best per pill | $750.78 $640.70 (15%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.55 | $76.54 (0%) | 🛒 Add to cart |
| 60 | $2.34 | $153.08 $140.18 (8%) | 🛒 Add to cart |
| 90 | $2.26 | $229.62 $203.82 (11%) | 🛒 Add to cart |
| 120 | $2.23 | $306.16 $267.46 (13%) | 🛒 Add to cart |
| 180 | $2.19 | $459.24 $393.88 (14%) | 🛒 Add to cart |
| 270 | $2.17
Best per pill | $688.86 $585.66 (15%) | 🛒 Add to cart |
Synonyms | |||
Solian (amisulpride) is an atypical antipsychotic medication specifically engineered for the treatment of schizophrenia. It functions by modulating dopamine activity in the brain, targeting both positive symptoms like hallucinations and delusions, and negative symptoms such as social withdrawal and apathy. Its selective receptor profile offers a distinct mechanism of action, providing clinicians with a potent tool for acute episodes and maintenance therapy. This agent is recognized for its efficacy in improving overall patient functioning and quality of life.
Features
- Active Ingredient: Amisulpride
- Pharmacological Class: Benzamide derivative; atypical antipsychotic
- Mechanism of Action: Selective antagonist at dopamine D2 and D3 receptors, with preferential action in limbic regions over striatal areas
- Bioavailability: Approximately 48% following oral administration
- Half-life: Average elimination half-life of 12 hours
- Dosage Forms: Available in film-coated tablets (50 mg, 100 mg, 200 mg, 400 mg) and oral solution
- Metabolism: Minimally metabolized; primarily excreted unchanged in urine
- Special Considerations: Dose adjustment required in renal impairment
Benefits
- Effectively reduces the intensity and frequency of positive psychotic symptoms, including hallucinations and delusions
- Demonstrates significant efficacy in ameliorating negative symptoms, such as blunted affect and avolition, which are often treatment-resistant
- Lower incidence of extrapyramidal symptoms (EPS) compared to typical antipsychotics, enhancing tolerability and adherence
- Minimal anticholinergic effects, reducing side effects like dry mouth and constipation
- Low propensity for weight gain and metabolic disturbances relative to some other atypical antipsychotics
- Improves overall social and occupational functioning, supporting reintegration and recovery
Common use
Solian is primarily indicated for the treatment of schizophrenia in adults. It is used both for managing acute exacerbations and for long-term maintenance therapy to prevent relapse. Its efficacy spans the symptomatic spectrum of the disorder, making it a versatile choice for comprehensive care. Off-label uses may include other psychotic disorders, though such applications require careful clinical judgment and are not formally approved.
Dosage and direction
The dosage of Solian must be individualized based on symptom profile, patient response, and tolerability. For positive symptoms, the recommended dosage range is 400–800 mg per day, administered in two divided doses. Doses exceeding 1200 mg daily are not recommended due to an increased risk of adverse effects. For predominant negative symptoms, lower doses of 50–300 mg per day may be effective. The tablets should be taken with water, with or without food. Dosage adjustments are necessary in patients with renal impairment; it is contraindicated in severe renal failure. Regular clinical assessment is essential to optimize therapeutic outcomes.
Precautions
Patients should be monitored for the emergence of sedation, especially during initial treatment or dose adjustments. Orthostatic hypotension may occur, particularly during titration; caution is advised in elderly patients and those with cardiovascular comorbidities. As with all antipsychotics, Solian may impair cognitive and motor skills; patients should be advised against driving or operating machinery until their response is known. Regular assessment of renal function is recommended. Electrolyte imbalances should be corrected before initiation. Use with caution in patients with Parkinson’s disease or Lewy body dementia due to the potential for exacerbating parkinsonian symptoms.
Contraindications
Solian is contraindicated in patients with known hypersensitivity to amisulpride or any excipients in the formulation. It must not be used in combination with levodopa. Contraindications also include pheochromocytoma, prolactin-dependent tumors (e.g., prolactinoma), and severe renal impairment (creatinine clearance <30 mL/min). Concomitant use with other drugs that prolong the QT interval is not recommended. It is contraindicated in breastfeeding women due to secretion into breast milk.
Possible side effects
Common side effects (≥1/100) include insomnia, anxiety, agitation, hyperprolactinemia (which may lead to galactorrhea, gynecomastia, or menstrual irregularities), and weight gain. Extrapyramidal symptoms such as akathisia, tremor, and dystonia may occur, though less frequently than with typical antipsychotics. Uncommon side effects (≥1/1000) include bradycardia, QT prolongation, hypotension, and constipation. Rare but serious adverse reactions include neuroleptic malignant syndrome, tardive dyskinesia, seizures, and venous thromboembolism. Any unusual or severe symptoms should be reported immediately.
Drug interaction
Solian may interact with other central nervous system depressants (e.g., alcohol, benzodiazepines, opioids), potentially enhancing sedative effects. Concomitant use with other drugs known to prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones) should be avoided due to additive risk. Levodopa and dopamine agonists may have reduced efficacy when co-administered. Caution is advised with drugs that inhibit renal excretion or alter electrolyte balance. Healthcare providers should review all concomitant medications before initiation.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to compensate for a missed one is not recommended. Patients should be educated on the importance of adherence and advised to contact their healthcare provider if multiple doses are missed.
Overdose
Symptoms of overdose may include severe sedation, coma, hypotension, tachycardia, and extrapyramidal symptoms. QT prolongation and arrhythmias are possible in significant overdoses. Management is supportive and symptomatic; there is no specific antidote. Gastric lavage may be considered if ingestion was recent. Cardiovascular monitoring, including ECG, is essential. Treatment should focus on maintaining airway, breathing, and circulation. Contact a poison control center immediately.
Storage
Store Solian tablets and oral solution at room temperature (15–30°C), in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Unused medication should be disposed of properly according to local regulations, not flushed or discarded in household trash.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Individual patient responses may vary. The prescribing physician should be guided by the official product information and clinical judgment.
Reviews
Clinical studies and post-marketing surveillance indicate that Solian is effective in reducing both positive and negative symptoms of schizophrenia, with a generally favorable tolerability profile. Many clinicians appreciate its selective receptor activity and lower metabolic burden compared to some alternatives. Some patients report improved engagement and functionality. However, hyperprolactinemia remains a notable concern in long-term use. Overall, it is regarded as a valuable option within the antipsychotic arsenal, particularly for patients with prominent negative symptoms or those intolerant of other agents.